Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.…
Larimar: Q3 Earnings Snapshot
Larimar Therapeutics (NASDAQ: LRMR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 71 employees.
The shares were at 3.140 USD on 20 November 2026, down 9.2% over 52 weeks. Its 52-week range is 1.915 USD to 6.420 USD: the price is 51.1% below the high and 64.0% above the low.
Its market capitalisation is 328.55M USD.
Larimar Therapeutics reports return on equity of -212.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 123.88M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 March 2027.